Q-omics provides the consensus-scored MIR1302-9HG profile across patient tissues and cancer cell-line models. MIR1302-9HG expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR1302-9HG is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, MIR1302-9HG RNA expression shows 13,202 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, STAD, and TGCT as cancer lineages where MIR1302-9HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1302-9HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1302-9HG survival associations across molecular data types. MIR1302-9HG RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1302-9HG RNA expression–survival associations across cancer types. High MIR1302-9HG expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in BLCA, UCEC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR1302-9HG RNA expression.
This table summarizes MIR1302-9HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1302-9HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1302-9HG shows lower tumor expression in THCA and PAAD and higher tumor expression in STAD, BLCA, KIRC and KICH. The STAD box plot shows higher MIR1302-9HG RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p = .005).
This table shows molecular features associated with MIR1302-9HG in patient tissues and cancer cell lines. In patient samples, MIR1302-9HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
